Lannett Adds To Respiratory Pipeline With Spiriva Rival
Extension Of Alliance With Respirent Targets $1.5bn US Brand Sales
Lannett has added another respiratory generic to its development partnership with China’s Respirent, in the form of a rival to Boehringer Ingelheim’s tiotropium-based Spiriva Handihaler.
